← All Candel Therapeutics, INC filings

Candel Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CADL
Candel Therapeutics, INC
10-K: Candel Therapeutics Advances Cancer Therapies, Secures Funding
Candel Therapeutics reports positive Phase 3 prostate cancer data, secures $100M royalty deal, and plans pivotal trials for lung cancer, extending its financial runway into Q1 2028.
NASDAQ
CADL
Candel Therapeutics, INC
10-K: Candel Therapeutics Reports Positive Phase 3 Data, Prolonged Survival in NSCLC and Pancreatic Cancer Trials in 10-K Filing
Candel Therapeutics' 10-K filing highlights positive clinical trial results for CAN-2409 in prostate, lung, and pancreatic cancers, along with progress in CAN-3110 for recurrent high-grade glioma.
NASDAQ
CADL
Candel Therapeutics, INC
10-K/A: Candel Therapeutics Files Amended 10-K to Include Omitted Part III Information
Candel Therapeutics has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
CADL
Candel Therapeutics, INC
10-K: Candel Therapeutics 10-K Filing: Focus on Viral Immunotherapy Pipeline
Candel Therapeutics' 10-K filing highlights its clinical-stage biopharmaceutical focus on developing viral immunotherapies for cancer treatment, with key updates on its CAN-2409 and CAN-3110 programs.